Drugs / Danirixin
Danirixin
also known as
GSK1325756 · DNX · Danirixin FB · danirixin free base (FB) · Danirixin HBr · danirixin hydrobromide · danirixin Hydrobromide (HBr) · Danirixina · +3 more
Small molecule targets CXCR2 via inhibition
Trials 15 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 19 trials | ||||||
| Phase 1 | NCT03457727 | Mar → Jul 2018 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT03136380 | May → Jul 2017 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT02453022 | May → Jul 2015 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT02169583 | Jun → Aug 2014 | respiratory tract infectious disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT02201303 | Jan 2014 → Jul 2015 | respiratory syncytial virus infectious disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01453478 | Oct → Dec 2011 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01267006 | Nov 2010 → Jan 2011 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01209104 | Apr → May 2010 | nutritional disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01209052 | Oct 2009 → Mar 2010 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 26 trials | ||||||
| Phase 2 | NCT03250689 | Nov 2017 → Oct 2018 | chronic obstructive pulmonary disease | GlaxoSmithKline | Terminated | No outcome recorded |
| Phase 2 | NCT03170232 | Oct 2017 → Nov 2018 | chronic obstructive pulmonary disease | GlaxoSmithKline | Terminated | No outcome recorded |
| Phase 2 | NCT03034967 | Apr 2017 → Oct 2018 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT02927431 | Jan → May 2017 | viral infectious disease | GlaxoSmithKline | Terminated | No outcome recorded |
| Phase 2 | NCT02469298 | Jun 2015 → Apr 2016 | viral infectious disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT02130193 | Feb 2014 → Aug 2016 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 16 cited values
Every value below carries the sentence it was read from. 16 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Danirixin | “Danirixin is a selective and reversible CXC chemokine receptor 2 antagonist that may be useful for the treatment of respiratory diseases such as chronic obstructive pulmonary disease.” PMID 31056840 ↗ May 201910“The pharmacokinetics and pharmacodynamics of danirixin (GSK1325756)--a selective CXCR2 antagonist” PMID 26092545 ↗ Jun 2015 |
| Known as | Danirixin FB | “Danirixin FB 50 mg IR Tablet is white, film-coated, capsule-shaped tablet for oral administration.” NCT02453022 ↗ |
| Known as | danirixin free base (FB) | “The primary objective of the study is to estimate the relative bioavailability of danirixin Hydrobromide (HBr) tablet, when compared to danirixin free base (FB).” NCT02453022 ↗ |
| Known as | Danirixin HBr | “Danirixin HBr 50 mg IR Tablet is white, film-coated, oval-shaped tablet for oral administration.” NCT02453022 ↗ |
| Known as | danirixin hydrobromide | “This study aimed to evaluate the safety, tolerability, and pharmacokinetics of danirixin after administration of single oral doses of 10, 50, and 100 mg danirixin hydrobromide...” PMID 31056840 ↗ May 2019 |
| Known as | danirixin Hydrobromide (HBr) | “The primary objective of the study is to estimate the relative bioavailability of danirixin Hydrobromide (HBr) tablet, when compared to danirixin free base (FB).” NCT02453022 ↗ |
| Known as | Danirixina | ChEMBL registry synonym — accepted as the source's own label CHEMBL3039531 ↗ |
| Known as | Danirixine | ChEMBL registry synonym — accepted as the source's own label CHEMBL3039531 ↗ |
| Known as | DNX | “Danirixin (DNX) is a selective CXC chemokine receptor (CXCR2) antagonist being developed as a potential anti-inflammatory agent for the treatment of COPD.” NCT03034967 ↗1“Danirixin (DNX) is a novel, selective, and reversible antagonist of the C-X-C chemokine receptor (CXCR) 2” NCT02927431 ↗ |
| Known as | GSK-1325756B | ChEMBL registry synonym — accepted as the source's own label CHEMBL3039531 ↗ |
| Known as | GSK1325756 | “Danirixin (GSK1325756) is a selective CXCR2 antagonist being developed as a potential anti-inflammatory agent for the treatment of COPD and influenza.” NCT03250689 ↗9“Evaluating the Effect of Danirixin (GSK1325756) on Lung Function and Health Related Quality of Life” NCT03170232 ↗ “The pharmacokinetics and pharmacodynamics of danirixin (GSK1325756)--a selective CXCR2 antagonist” PMID 26092545 ↗ Jun 2015 “Danirixin (GSK1325756) Co-administered With a Standard-of-care Antiviral (Oseltamivir)” NCT02927431 ↗ “Evaluation of Danirixin (GSK1325756) Inhibition of CD11b Cell Surface Expression” NCT02201303 ↗ “Oral Danirixin (GSK1325756) in Symptomatic COPD Subjects” NCT02130193 ↗ “GSK1325756 (Danirixin)” NCT02469298 ↗ |
| Known as | GSK1325756H | “Part 1 will be a double blind, placebo-controlled, 3-period crossover, ascending single oral dose administration of GSK1325756H (Hydrobromide Salt Tablet Formulations of...” NCT03136380 ↗ |
| Action | Inhibit | “CXCR2 antagonist” NCT01453478 ↗ |
| Modality | Small molecule | “Danirixin, is a small molecule, CXCR2 antagonist being evaluated as a potential anti-inflammatory medicine.” PMID 26092545 ↗ Jun 2015 |
| Route | Oral | “single ascending and repeat oral doses of danirixin” PMID 26092545 ↗ Jun 2015 |
| Target | CXCR2 | “interleukin 8 receptor (IL8R also known as CXCR2)” NCT01453478 ↗ |